Yılmaz KIROĞLU, Mine CİNBİŞ, Mevlüt BİCAN, Aziz POLAT

Metotreksat tedavisine bağlı nörotoksisite gelişen iki olgununklinik ve radyolojik incelemesi

Metotreksat, akut lenfoblastik lösemi, lenfoma veya osteosarkom gibi neoplastik hastalıkların tedavisinde kullanılan antimetabolit grubu bir kemoterapötik ajandır. Metotreksatın myelosüpresyon, mukozit, hepatik ve tubüler nekroz ile santral sinir sistemi toksisitesi gibi değişik yan etkileri bulunmaktadır. Bu makalede akut lenfoblastik lösemi tanısı alan iki olguda metotreksat kullanımı sonucu gelişen santral sinir sistemi nörotoksisitesinin klinik ve radyolojik bulguları ile uzun dönem izlemleri sunulmuştur.

The clinical and radiological investigation of two cases with neurotoxicıty folowing methotrexate treatment

Methotrexate is a chemotherapeutic agent which is a member of antimetabolite group drugs, and used in neoplastic diseases such as acute lymphoblastic leukemia, lymphoma and osteosarcoma. Methotrexate has various side effects such as myelosuppression, mucositis, hepatic and tubular necrosis, central nervous system toxicities. In this article, clinical and radiological findings and longterm follow-up of two cases with central nervous system neurotoxicity following methotrexate treatment are presented.

PDF

___

1. Aicardia J. Tumours and vascular disorders. In: Aicardia J, ed, 2nd edition. Diseases of the Nervous System in Childhood. London: Cambridge University Pres; 1998: p. 513-6.
2. Mahoney DH Jr, Shuster JJ, Nitschke R et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediatedose intravenous methotrexate and intrathecal triple therapy a pediatric oncology group study. J Clin Oncol 1998; 5: 1712-22.
3. Gagliano RG, Costanzi JJ. Paraplegia following intrathecal methotrexate: report of a case and review of the literatüre. Cancer 1976; 37: 1663-8.
4. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998; 245: 695-708.
5. Bernini JC, Fort DW, Griener JC et al. Aminophylline for methotrexate- induced neurotoxicity. Lancet 1995; 345: 544-7.
6. Anderson SC, Baquıs GD, Jackson A et al. Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. Muscle Nerve 2002; 25:106-10.
7. Jaffe N, Takaue Y, Anzai T et al. Transient neurolojic disturbances induced by high- dose methotreksate treatment. Cancer 1985 ;56: 1356-60.
8. Menkes JH, Fink BW, Hurvitz CGH et al. Neurologic manifestations of systemic disease. Child Neurology, 6th ed. Lippincott Williams and Wilkins, Philadelphia: 2000; 1093-154.
9. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994; 20: 191-214.
10. Vezmar S, Becker A, Bode U et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92-104.
11. Walker RW, Allen JC, Rosen G et al. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986; 4:1845-50.
12. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation. A new classification. Cancer Treat Rep 1981; 65 suppl 1: 89-98.
13. Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Semin Oncol 1982; 9: 103-30.
14. Fritsch G, Urban C. Transient encephalopathy during the late course of treatment with high-dose methotrexate. Cancer 1984; 53: 1849-51.
15. Chen CY. Childhood leukemia: central nervous system abnormalities during and after treatment. AJNR Am J Neuroradiol 1996 17:295-310.
16. Tekşam M, Casey SO, Michel E et al. Posterior reversibl ensafalopati sendromu: patofizyoloji ve ileri MRG teknikleri ile korelasyon. Tani Girisim Radyol 2001; 7: 464-72.